Mr Gandolfo has over 21 years of experience as CFO of private and publicly held companies with a primary focus in the life sciences, healthcare and medical device sectors. He has had direct responsibility over private and public capital raising, financial management, mergers and acquisition transactions and SEC reporting throughout his professional career.
Previous to this appointment, Mr Gandolfo was CFO of Power Medical Interventions (PMI), a publicly held medical device company that manufactures and markets computer assisted endo-mechanical surgical instruments. With PMI, Mr Gandolfo raised approximately $75 million in 2007 through a convertible debt offering and IPO of common stock.
George Goldberger, Progenitor Cell Therapy’s (PCT’s) chief business and financial officer for the past 10 years, will now focus on growing PCT’s sales, marketing and corporate development activities, with emphasis on expanding PCT’s presence in Europe and Asia, the company said.
Andrew Pecora, PCT’s CEO, said: “We are very pleased to add someone with such depth of experience to our executive management team. With PCT expecting to close its current round of expansion fundraising soon, we will value his experience and focus on the fiscal health of the company and investor return while we continue to expand and position the company in this rapidly growing field of cell therapies and regenerative medicine.”